SFG
ALNY icon

SevenBridge Financial Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

SevenBridge Financial Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-100
Closed -$6K – 621
2016
Q2 		$6K Buy
+100
New +$6.3K ﹤0.01% 563

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

SevenBridge Financial Group's ALNY Position: Q3 2016 in Review

SevenBridge Financial Group sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2016, closing a stake of 100 shares — an estimated $6K sold.

SevenBridge Financial Group first reported a position in ALNY in Q2 2016 and held it in 1 quarter. The position peaked at $6K in Q2 2016. 260 funds tracked by Wall St. Rank hold ALNY as of Q3 2016.

  • SevenBridge Financial Group reported no remaining Alnylam Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • SevenBridge Financial Group sold 100 Alnylam Pharmaceuticals shares in Q3 2016, an estimated $6K.
  • SevenBridge Financial Group first reported a position in Alnylam Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • SevenBridge Financial Group's Alnylam Pharmaceuticals position peaked at $6K in Q2 2016.
  • 260 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2016.

Based on SevenBridge Financial Group's 13F filing for Q3 2016, filed 28 Nov 2016.